39周妊娠择期引产:一项大型多中心随机对照试验的意义
2018年8月8日Grobman等发表ARRIVE试验,对比39周择期引产与期待管理,发现主要结局新生儿 morbidity 复合指标两组无差异,择期引产组剖宫产率和妊娠期高血压疾病率降低。本文回顾择期引产历史和文献,讨论该试验对临床实践和卫生政策的影响。
要点
- 39周择期引产与期待管理相比,主要新生儿 morbidity 复合结局无差异。
- 择期引产组剖宫产率和妊娠期高血压疾病率降低。
- 该试验为迄今解决择期引产争议的最佳证据。
核心结论
- 39周择期引产与期待管理相比,主要新生儿 morbidity 复合结局无差异,择期引产组剖宫产率和妊娠期高血压疾病率降低。
研究设计与样本
- ARRIVE试验为大型随机对照试验,由尤尼斯·肯尼迪·施莱佛国家儿童健康与人类发展研究所母胎医学单位网络开展,纳入39周妊娠初产妇,比较择期引产与期待管理。
主要发现
- 主要结局新生儿 morbidity 复合指标两组无差异,择期引产组剖宫产率和妊娠期高血压疾病率降低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On August 8, 2018, Grobman et al published the findings from the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial, a large randomized controlled trial of elective induction of labor in nulliparous women at 39 weeks of gestation compared with expectant management. Conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, the trial found there was no difference between the two groups in the primary outcome, a composite of neonatal morbidity. Also, there was a reduction in rates of cesarean delivery and hypertensive disorders of pregnancy in the elective induction group. The topic of elective induction has been of interest to clinicians for decades, and research has yielded inconsistent results in the past. This trial offers the best evidence thus far to address this complex issue. Our objective is to briefly review the history and literature regarding elective induction of labor, discuss the recently published ARRIVE trial, and consider its implications on clinical practice and health policy.
引用
- Marrs C, La Rosa M, Caughey A, et al. Elective Induction at 39 Weeks of Gestation and the Implications of a Large, Multicenter, Randomized Controlled Trial. Obstet Gynecol. 2019. PMID: 30741803. doi:10.1097/AOG.0000000000003137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。